Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder

Journal of Clinical Psychiatry

Volumn 59, Issue 6, 1998, Pages 306-312

  Wheatley, David P ^a   Van Moffaert, Miriam ^b   Timmerman, Leo ^c   Kremer, Charlotte M E ^d   Priest, R G ^e   Guirguis W R , ^e   Mutiboko, I K ^e   Green, M C D ^e   Willmotte, J ^e   Bollen, J ^e   Demyttenaere, K ^e   De Bleeker, E ^e   De Weirdt, L ^e   Van Beek, H E M ^e   Coppens, M G ^e   Vegt, M ^e   Reimitz, P E ^e  

^a Royal Masonic Hospital   (United Kingdom)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Delta Psychiatrisch Ziekenhuis   (Netherlands)

^d NV ORGANON   (Netherlands)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; CLONIDINE; DOXEPIN; FLUOXETINE; GUANETHIDINE; MIRTAZAPINE; NITRAZEPAM; NORTRIPTYLINE; OXAZEPAM; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRAZODONE; VENLAFAXINE;

ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; TREATMENT OUTCOME; TREMOR; XEROSTOMIA;

EID: 0031927915     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n0606     Document Type: Article

References (32)

1. Claghorn JL. Mirtazapine: a novel noradrenergic and specific serotonergic antidepressant. Today's Therapeutic Trends 1996;14:141-164
2. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl4):19-25
3. Delbressine LPC, Voss RME. The clinical relevance of preclinical data: mirtazapine, a model compound. J Clin Psychopharmacol 1997;17(suppl 1):29S-34S
4. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-525
5. Claghom JL, Lesem MD. A double-blind, placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-171
6. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depression. Psychopharmacol Bull 1990;26:191-196
7. van Moffaert M, de Wilde J, Veerecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995;10:3-9
8. Mullin J, Lodge A, Bennie E, et al. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with depression. J Psychopharmacol 1996;10:235-240
9. Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6 week randomized double-blind trial in hospitalized depressed patients. Hum Psychopharmacol 1995;10:173-180
10. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995;10:263-271
11. Marttila M, Jääskälainen J, Järvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995;5:441-446
12. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of depression. CNS Drugs 1996;5: 389-402
13. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995;10(suppl 4):25-36
14. Kasper S, Zivkov M, Roes KCB, et al. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 1997;7:115-124
15. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10(suppl 4):37-45
16. Nutt D. Mirtazapine: its pharmacology in relation to adverse effects. Acta Psychiatr Scand. In press
17. Sussman N, Stahl S. Update in the pharmacotherapy of depression. Am J Med 1996;101(suppl 6A):26S-36S
18. Benfield P, Ward A. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:313-334
19. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306: 683-687
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
22. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
23. Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 1971;10:181-191
24. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-218
25. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29: 321-326
26. World Health Organization. Adverse Reactions Terminology (WHO-ART). World Health Organization: Geneva, Switzerland; 1994
27. Koch GC, Karr J. Categorical data analysis. In: Berry DA, ed. Statistical Methodology in Pharmaceutical Sciences. New York, NY: Marcel Dekker; 1990:389-473
28. Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol 1994;4:283-284
29. Rappaport M, Coccaro E, Sheline Y, et al. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996;16:373-378
30. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
31. Roose SP, Classman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-1739
32. Clerc GE, Ruimy P, Verdeau-Pailläs J, for the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143